Blog
RSS FeedPosted by Michael Wonder on 08 Dec 2022
IQWiG updates its General Methods
6 December 2022 - Revision of the cost-benefit assessment and addition of the concept of application-accompanying data collection: Comments on ...
Posted by Michael Wonder on 08 Dec 2022
Osteoporosis after menopause: fewer vertebral fractures with teriparatide than with risedronate
5 December 2022 - The final report of the IQWiG on the comparative benefit assessment of bisphosphonates, teriparatide and denosumab ...
Posted by Michael Wonder on 07 Dec 2022
Differences in evidentiary requirements between European Medicines Agency and European health technology assessment of oncology drugs—can alignment be enhanced?
5 December 2022 - National health technology assessments across Europe show differences in evidentiary requirements from assessments by the EMA, affecting ...
Posted by Michael Wonder on 06 Dec 2022
Germany's use of reference pricing for biologics: lessons for the US
5 December 2022 - A redesign of consumer cost sharing in the US is important to accelerate the adoption of biosimilars ...
Posted by Michael Wonder on 01 Dec 2022
Early breast cancer: indication of a minor additional clinical benefit of adjuvant therapy with olaparib
1 December 2022 - Adjuvant treatment with olaparib can prolong life and prevent recurrence in early breast cancer. However, it ...
Posted by Michael Wonder on 03 Nov 2022
Advanced cervical cancer: pembrolizumab prolongs life
2 November 2022 - There is a hint of a major added benefit compared to chemotherapy with cisplatin or carboplatin, each ...
Posted by Michael Wonder on 27 Oct 2022
Evidence based drug delivery for rare diseases: the role of digitisation
25 October 2022 - Digitisation has potential when it comes to making clinical development for the care of rare diseases more ...
Posted by Michael Wonder on 26 Oct 2022
Germany significantly tightens drug pricing and reimbursement laws
26 October 2022 - The German regulation of pricing and reimbursement of pharmaceuticals is probably one of the most complicated legal ...
Posted by Michael Wonder on 07 Oct 2022
COVID-19: nirmatrelvir/ritonavir reduces the risk of a severe course in patients at risk
4 October 2022 - However, due to contra-indications and interactions, the combination of active ingredients is not suitable for all patients ...
Posted by Michael Wonder on 06 Oct 2022
Palbociclib combination in advanced breast cancer: again only disadvantages
5 October 2022 - For post-menopausal women with hormone receptor positive, HER2 negative breast cancer in the first line, there is ...
Posted by Michael Wonder on 19 Sep 2022
Registry-based randomised trials: the best of both worlds?
15 September 2022 - IQWiG authors present the advantages and disadvantages of study designs that combine explanatory and pragmatic aspects. ...
Posted by Michael Wonder on 08 Sep 2022
Is IQWiG's 15% threshold universally applicable in assessing the clinical relevance of patient reported outcomes changes? An ISPOR Special Interest Group report.
8 September 2022 - To assess the clinical relevance of patient reported outcomes, a response threshold of ≥ 15% of the ...
Posted by Michael Wonder on 01 Sep 2022
Availability of new medicines in the US and Germany (2004 - 2018)
30 August 2022 - In this cohort study comparing 599 medicine approvals in the US and Germany between 2004 and 2018, ...
Posted by Michael Wonder on 23 Aug 2022
The EU HTA regulation: a new frontier for access to innovative technologies
23 August 2022 - A new health technology regulation is due to be applied to help EU countries determine the effectiveness ...
Posted by Michael Wonder on 17 Aug 2022
IQWiG annual report for 2021 is available
17 August 2022 - The IQWiG has published its 2021 annual report today. ...